Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A MULTICENTER, OPEN LABEL, PHARMACOKINETICS, PHARMACODYNAMICS AND SAFETY STUDY OF ELELYSO(TM) (TALIGLUCERASE ALFA) IN PEDIATRIC SUBJECTS WITH TYPE 1 GAUCHER DISEASE

Trial Profile

A MULTICENTER, OPEN LABEL, PHARMACOKINETICS, PHARMACODYNAMICS AND SAFETY STUDY OF ELELYSO(TM) (TALIGLUCERASE ALFA) IN PEDIATRIC SUBJECTS WITH TYPE 1 GAUCHER DISEASE

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 28 Dec 2018

At a glance

  • Drugs Taliglucerase alfa (Primary)
  • Indications Gaucher's disease type I
  • Focus Pharmacokinetics
  • Sponsors Pfizer
  • Most Recent Events

    • 05 Sep 2018 Status changed from not yet recruiting to recruiting.
    • 08 Aug 2018 Planned initiation date changed from 1 Jul 2018 to 1 Aug 2018.
    • 03 Jul 2018 Planned initiation date changed from 1 Jun 2018 to 1 Jul 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top